Atrility
Madison, US · Founded 2017 · 1 known investors
Find your way into Atrility
260 people in our graph share verified history with the Atrility team — schools, employers, funds. One of them is your warm intro.
Kevin Rileyunlockedknows Sean McCormick · together at Miami University (overlapped)
×4knows the team · via Miami University
×4knows the team · via Thermo Fisher Scientific
×3knows the team · via Harvard Extension School
Atrility develops cardiac medical devices, including the AtriAmp for post-operative arrhythmia monitoring, aimed at improving care for cardiac patients. The company combines healthcare, business, and engineering expertise to bring medical technology to market.
Founders & leadership
Atrility was founded in 2017 by Matt Knoespel, Phil Terrien, Nick Von Bergen, M.D., and Pete Lukszys.
MK
Matt KnoespelVP of Commercialization, Founder
PT
Phil TerrieninVP of Operations, Founder
NV
Nick Von Bergen, M.D.CMO, Board Member, Founder
PL
Pete LukszysSenior Advisor, Founder
SM
Sean McCormickinCEO, Board MemberSean McCormick is a physician with over 20 years of clinical and industry experience, now CEO of Atrility, which develops cardiac medical devices including the AtriAmp for post-operative arrhythmia monitoring. He has expertise in creating data-driven healthcare strategies and working across clinical, business, and engineering domains.
MB
Mike BressCFO
NV
Nicholas Von BergenNamed on SEC filing
Board
CE
MP
Michael PartschBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$5M disclosed across 4 rounds · 2018–2025
▶$1MraisedFeb 2026 · 3 investors · Other Health CareRule 506(b)
▶$1MraisedFeb 2026 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Sean McCormickExecutive Officer, Director
- Christopher EckstromDirector
- Nicholas Von BergenDirector
- Michael PartschDirector
- Offering amount
- $2M
- Amount sold
- $1M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.4MraisedJun 2022 · 15 investors · Other Health CareRule 506(b)
▶$3.4MraisedJun 2022 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Chris R. EckstromDirector
- Michael J. PartschDirector
- Nicholas Von BergenDirector, Promoter
- Peter LukszysExecutive Officer, Promoter
- David B. KaysenExecutive Officer, Director, Promoter
- Offering amount
- $3.8M
- Amount sold
- $3.4M
- Minimum investment
- $20K
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$300KraisedOct 2020 · 1 investors · Other Health CareRule 506(b)
▶$300KraisedOct 2020 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas Von BergenExecutive Officer, Director
- Peter LukszysExecutive Officer, Director
- Offering amount
- $700K
- Amount sold
- $300K
- Minimum investment
- $25K
- Proceeds to insiders
- $20K
- First sale
- Sep 2020
- Incorporated
- Limited Liability Company, Wisconsin, 2017
- Federal exemptions
- 06b
▶$310KraisedApr 2018 · 7 investors · Other Health CareRule 506(b)
▶$310KraisedApr 2018 · 7 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter LukszysExecutive Officer, Director
- Nicholas Von BergenExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $310K
- Minimum investment
- $15K
- First sale
- Feb 2018
- Incorporated
- Limited Liability Company, Wisconsin, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Irhythmtech3 shared keywordsiRhythm provides wearable cardiac monitoring devices and AI-powered analysis services for clinicians to diagnose heart arrhythmias. The platform combines engineered ECG monitors, machine learning algorithms, and expert clinical review to deliver actionable diagnostic reports.
Boston Scientific3 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Companies competing with Atrility for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Atrility do?
- Atrility develops cardiac medical devices, including the AtriAmp for post-operative arrhythmia monitoring, aimed at improving care for cardiac patients. The company combines healthcare, business, and engineering expertise to bring medical technology to market.
- Who founded Atrility?
- Atrility was founded by Matt Knoespel, Phil Terrien, Nick Von Bergen, M.D., Pete Lukszys in 2017.
- Who are Atrility's investors?
- Atrility's investors include Rock River Capital Partners.
- How much funding has Atrility raised?
- Atrility has disclosed $5M raised across 4 rounds.
- Where is Atrility headquartered?
- Atrility is headquartered in Madison, US.